Literature DB >> 31566915

The role of sex in particle-induced inflammation and injury.

Jessica L Ray1, Paige Fletcher1, Rachel Burmeister1, Andrij Holian1.   

Abstract

The use of engineered nanomaterials within various applications such as medicine, electronics, and cosmetics has been steadily increasing; therefore, the rate of occupational and environmental exposures has also increased. Inhalation is an important route of exposure to nanomaterials and has been shown to cause various respiratory diseases in animal models. Human lung disease frequently presents with a sex/gender-bias in prevalence or severity, but investigation of potential sex-differences in the adverse health outcomes associated with nanoparticle inhalation is greatly lacking. Only ~20% of basic research in the general sciences use both male and female animals and a substantial percentage of these do not address differences between sexes within their analyses. This has prevented researchers from fully understanding the impact of sex-based variables on health and disease, particularly the pathologies resulting from the inhalation of particles. The mechanisms responsible for sex-differences in respiratory disease remain unclear, but could be related to a number of variables including sex-differences in hormone signaling, lung physiology, or respiratory immune function. By incorporating sex-based analysis into respiratory nanotoxicology and utilizing human data from other relevant particles (e.g., asbestos, silica, particulate matter), we can improve our understanding of sex as a biological variable in nanoparticle exposures. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  engineered nanomaterials; gender; inhalation; respiratory diseases; sex

Mesh:

Substances:

Year:  2019        PMID: 31566915     DOI: 10.1002/wnan.1589

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  7 in total

1.  Nanoparticle-Induced Airway Eosinophilia Is Independent of ILC2 Signaling but Associated With Sex Differences in Macrophage Phenotype Development.

Authors:  Jessica L Ray; Pam K Shaw; Britten Postma; Celine A Beamer; Andrij Holian
Journal:  J Immunol       Date:  2021-11-24       Impact factor: 5.422

2.  Dietary Docosahexaenoic Acid as a Potential Treatment for Semi-acute and Chronic Particle-Induced Pulmonary Inflammation in Balb/c Mice.

Authors:  Paige Fletcher; Raymond F Hamilton; Joseph F Rhoderick; Britten Postma; Mary Buford; James J Pestka; Andrij Holian
Journal:  Inflammation       Date:  2021-10-15       Impact factor: 4.092

Review 3.  Lung Models to Evaluate Silver Nanoparticles' Toxicity and Their Impact on Human Health.

Authors:  Jesús Gabriel González-Vega; Juan Carlos García-Ramos; Rocio Alejandra Chavez-Santoscoy; Javier Emmanuel Castillo-Quiñones; María Evarista Arellano-Garcia; Yanis Toledano-Magaña
Journal:  Nanomaterials (Basel)       Date:  2022-07-05       Impact factor: 5.719

4.  Contribution of Particle-Induced Lysosomal Membrane Hyperpolarization to Lysosomal Membrane Permeabilization.

Authors:  Tahereh Ziglari; Zifan Wang; Andrij Holian
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 5.  Nanomaterials and hepatic disease: toxicokinetics, disease types, intrinsic mechanisms, liver susceptibility, and influencing factors.

Authors:  Ting Sun; Yiyuan Kang; Jia Liu; Yanli Zhang; Lingling Ou; Xiangning Liu; Renfa Lai; Longquan Shao
Journal:  J Nanobiotechnology       Date:  2021-04-16       Impact factor: 10.435

Review 6.  Susceptibility Factors in Chronic Lung Inflammatory Responses to Engineered Nanomaterials.

Authors:  Dorothy J You; James C Bonner
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

7.  Health risk assessment of PM2.5 on walking trips.

Authors:  Caihua Zhu; Zekun Fu; Linjian Liu; Xuan Shi; Yan Li
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.